Real story · 25 Apr 2026

The Last Border Has Fallen: Tasmania Just Ended Australia's ADHD Postcode Lottery — But Only Halfway

On 16 February 2026, a Tasmanian pharmacist handed a woman her Vyvanse. There was no fanfare, no press conference at the counter. But two weeks earlier, that same woman, holding that same interstate script from her Melbourne psychiatrist, w

On 16 February 2026, a Tasmanian pharmacist handed a woman her Vyvanse. There was no fanfare, no press conference at the counter. But two weeks earlier, that same woman, holding that same interstate script from her Melbourne psychiatrist, would have walked out empty-handed. For years, Tasmania had been the last Australian state where a valid interstate prescription for Schedule 8 ADHD stimulants was, effectively, a piece of paper with no legal weight. Then, quietly, the border fell.

The reform — the Poisons Amendment (Interstate Prescriptions) Act 2025, which commenced on 16 February 2026 — allows Tasmanian pharmacists to dispense almost any medicine written by an AHPRA-registered practitioner from anywhere in Australia. That includes ADHD psychostimulants, opioids, medicinal cannabis and benzodiazepines. The Pharmaceutical Society of Australia welcomed the change with the line "no longer an outlier", and it was right. Every other state and territory had already harmonised. Tasmania, at long last, caught up.

For the roughly 650,000 Australians who are AuDHD — living with both autism and ADHD — this change is more than administrative housekeeping. It is a case study in how the geography of your letterbox still decides whether your brain gets the medication it needs. And it is a warning, because Tasmania's reform fixed dispensing. It did not fix the larger, messier, and much more consequential postcode lottery sitting underneath it: who is allowed to diagnose you, who is allowed to start your medication, and how long you will wait.

The quiet reason a dispensing fix matters for AuDHD Australians

AuDHD sits at a diagnostic crossroads that makes cross-border care common rather than exotic. Research now estimates that 50 to 70 per cent of autistic people meet criteria for ADHD, and that a third or more of people with an ADHD diagnosis also meet criteria for autism. Mellahn and colleagues, in a 2022 Australian cross-sectional survey of 505 children published in Frontiers in Psychiatry, found that the co-occurring ADHD-plus-autism group had the highest rate of polypharmacy — 52 per cent, compared with 21 per cent for ADHD alone and 22 per cent for autism alone. Eighty-six per cent of the ADHD-plus-autism children were on at least one medication, most often a stimulant combined with melatonin.

That is an enormous, complicated, highly individualised prescribing story. And because so few Australian clinicians are genuinely comfortable assessing and medicating AuDHD — particularly in adults and particularly in women — the families and individuals who do find a good specialist often find them one or two states away. A woman diagnosed at 42 in Melbourne and medicated by a Sydney psychiatrist on telehealth. A teenager assessed by a Brisbane paediatrician while the family drives seven hours home to Mount Isa. A Tasmanian whose only experienced AuDHD psychiatrist runs a practice in Adelaide. Until February, that Tasmanian had no legal way to fill that script on the island where she lived.

Harmonising dispensing matters. But dispensing is the last step. The earlier steps — diagnosis and initial prescribing — are where the lottery still lives.

Six states, six rulebooks, one brain

Across Australia, the rules for who can diagnose ADHD and who can start a patient on stimulants remain a patchwork that would embarrass a first-year policy student. Queensland has been the most permissive for nearly a decade, allowing GPs to diagnose and prescribe ADHD medications for children since 2017, and extending those rights to adults in December 2025. New South Wales moved next: since September 2025, GPs have been able to continue stimulant prescriptions for patients over six with an existing diagnosis, and from early 2026 "endorsed prescribers" who complete accredited training can commence prescribing for patients of all ages.

Victoria sits closer to the other end of the scale. Victorian GPs can continue-prescribe ADHD stimulants to a patient only after a specialist has made the initial diagnosis, and the patient must be reviewed by that specialist at least every two years. The Victorian government has committed A$750,000 to train an initial 150 GPs by September 2026, but in the meantime families still wait for specialist appointments that routinely cost $1,400 to $3,500 out of pocket and stretch 6 to 12 months.

Tasmania, even after the February reform, has yet to announce a broad GP-initiation pathway equivalent to Queensland's or New South Wales's. South Australia is moving towards mandatory real-time prescription monitoring. The Australian Capital Territory, the Northern Territory and Western Australia each run their own Chief Health Officer approval pathways. From 11 February 2026, a Standing CHO Approval in some jurisdictions now allows trained GPs to prescribe ADHD stimulants for patients aged six and over without individual patient-level approval — but only where the state has opted in and the GP has done the training.

Overlay that map on a country where specialist psychiatrists are concentrated in capital cities, where adult autism assessment is almost entirely outside Medicare, and where AuDHD-literate clinicians are rarer still, and the implication is stark: your ability to be diagnosed, medicated and reviewed depends substantially on where you live and how much you can spend.

A shortage that masked a structural problem

For most of 2025, that structural unfairness was hidden behind an acute crisis. Methylphenidate products — including Concerta, Ritalin LA and Rubifen LA — went into rolling shortage, driven partly by a doubling of PBS prescriptions to more than three million and partly by global manufacturing capacity failing to keep up. The Therapeutic Goods Administration invoked section 19A of the Therapeutic Goods Act 1989 to approve overseas-registered methylphenidate products as interim supply. Concerta and Ritalin LA shortages have now largely resolved; the TGA advises that Rubifen LA shortages are expected to resolve by the end of June 2026, and section 19A overseas approvals for methylphenidate are set to end in late April 2026.

Lisdexamfetamine — Vyvanse — has its own parallel story, partly caused by a European packaging site receiving a Statement of Non-Compliance with Good Manufacturing Practice that saw batches quarantined before they reached Australian pharmacies. Generic versions remain patchier than brand Vyvanse.

The shortage taught the country something it mostly already knew: when the supply chain wobbles, people with ADHD and AuDHD lose sleep, lose jobs, lose stability, and lose trust in the system that was supposed to be treating them. What it also revealed, less loudly, is that the medicine itself was never the whole problem. The ability to access medicine — to be seen, diagnosed, prescribed, reviewed, and dispensed — is a multi-step chain, and the chain breaks at different links in different states.

What a real fix would look like

The Australasian ADHD Professionals Association's 2022 evidence-based clinical guideline — endorsed by the RACGP, RANZCP and a dozen other bodies — already recommends that, for people with autism or intellectual disability, prescribers should start with low doses and titrate slowly. That is good clinical advice. It is not, however, a national prescribing framework. Health ministers have reportedly been pushing for GP ADHD prescribing rights nationally, and a twelve-month harmonisation plan is said to be reporting back early in 2026, aimed at smoothing state drugs-and-poisons legislation so decisions about which practitioners may prescribe can be made once, not eight times.

AuDHD Australians have specific asks that any harmonisation should honour. The first is national recognition of GP-initiated ADHD diagnosis, backed by accredited training that explicitly includes autism co-occurrence. The second is a Medicare item number for dual AuDHD assessment, so that the cost of being properly worked up does not sit, as it does today, almost entirely with the patient. The third is an AuDHD-specific prescribing pathway in the next iteration of the AADPA guideline — one that names co-occurring autism, sensory sensitivity and slower titration as the default assumption, not the exception. And the fourth, perhaps the most deceptively simple, is a single national shortage dashboard so that a parent in Launceston and a parent in Darwin see the same information on the same day.

The border that still matters

Tasmania's reform is worth celebrating. It removes a category of pointless suffering — the suffering of holding a valid script that no one near you is legally allowed to dispense. But the larger border still stands. It is the border between states with GP-initiated pathways and states without. Between metro specialists and rural families. Between those who can afford a $3,500 private dual assessment and those who cannot. Between clinicians who understand AuDHD and clinicians who still treat autism and ADHD as unrelated files on separate desks.

The woman who walked out of that Hobart pharmacy in February did not make news. Perhaps that is the most important part. What AuDHD Australians have been asking for is not attention. It is a system that, no matter where the letterbox sits, treats their brains as if they were worth the same care. One border has fallen. The rest are still waiting.

Sources

Have a story to share?

We publish lived experience

Anonymous submissions welcome. Edited gently for clarity, never to push a narrative.

Email us Read more stories